Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322761 | 1.00 | CYP1A2 (0.54) | CYP1A2ALDH1A1EPHX1PPARGGRM2 | |
| SCHEMBL9322994 | 1.00 | CYP1A2 (0.54) | CYP1A2ALDH1A1EPHX1PPARGGRM2 | |
| SCHEMBL5452024 | 0.92 | LMNA (0.45) | CYP1A2ALDH1A1PPARGGRM2LMNA | |
| SCHEMBL5450456 | 0.86 | — | — | |
| SCHEMBL8396437 | 0.82 | CYP1A2 (0.60) | CYP1A2ALDH1A1EPHX1PPARGGRM2 | |
| Hexane SCHEMBL17769241 | 0.81 | PTPN1 (0.43) | CYP1A2ALDH1A1LMNAMAOASLC6A2 | |
| SCHEMBL18595269 | 0.78 | LMNA (0.38) | CYP1A2ALDH1A1LMNAMAOASLC6A2 | |
| SCHEMBL18595192 | 0.78 | LMNA (0.38) | CYP1A2ALDH1A1LMNAMAOASLC6A2 | |
| SCHEMBL8761955 | 0.78 | ALDH1A1 (0.56) | CYP1A2ALDH1A1LMNAMAOASLC6A2 | |
| SCHEMBL9324248 | 0.78 | ALDH1A1 (0.56) | CYP1A2ALDH1A1LMNAMAOASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030129191-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-07-10 | — | — | US | claimed |
| US-6416738-B1 | ADMINISTERING TO A RECIPIENT A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND A MEMBER OF A LIGAND/ANTI-LIGAND BINDING PAIR, THEREAFTER ADMINISTERING TO THE RECIPIENT A CLEARING AGENT, ADMINISTERING SECOND CONJUGATE | NEORX CORPORATION | 2002-07-09 | — | — | US | claimed |
| US-6075010-A | Small molecular weight ligand-hexose containing clearing agents | NEORX CORPORATION (US) | 2000-06-13 | — | — | US | claimed |
| EP-0743956-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | claimed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-7060689-B2 | Injection of chemical intermediates into mammalian cells; obtain cells, inject with ligand joined colloid, detect signal from ligand | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-06-13 | — | — | US | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1997046098-A1 | CLUSTER CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5624896-A | Clearing agents useful in pretargeting methods | NEORX CORPORATION (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129191-A1 | Pretargeting methods and compounds | BTD, HLCS, STRA6 | CYP1A2 4699/4885ALDH1A1 1840/4885EPHX1 2032/4885 |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRM1 | CYP1A2 1861/4885ALDH1A1 975/4885EPHX1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.